Heart failure is a pressing global health concern that poses challenges in management and treatment. However, there are effective tools available, such as guideline-directed medical therapy (GDMT), that can significantly improve outcomes for individuals with heart failure.
A recent study led by UCLA sheds light on the crucial role that these guidelines play in reducing mortality rates for individuals suffering from heart failure with reduced ejection fraction (HFrEF), a form of heart failure affecting millions worldwide. Dr. Amber Tang, the lead author of the study, emphasized that these guidelines are underutilized in clinical settings globally due to barriers like poor health literacy, limited access to care, and medication costs.
Published in JAMA Cardiology, the study revealed that a large number of individuals with HFrEF who were eligible for life-saving treatments did not receive them. The estimated figures were staggering: 8.2 million individuals for beta blocker treatment, 20.4 million for angiotensin receptor neprilysin inhibitors treatment, 12.2 million for mineralocorticoid receptor antagonists treatment, and 21.2 million for SGLT2 inhibitors treatment, highlighting the challenges in implementing these guidelines on a global scale.
Despite these obstacles, the researchers projected that optimal implementation of GDMT could prevent 1.2 million deaths annually worldwide, with significant lives saved in regions like the Eastern Mediterranean, Southeast Asia, and Western Pacific. This study, which analyzed existing patient data from large registries, provided estimates on heart failure prevalence, GDMT eligibility, current prescription rates, and potential lives saved across the world, marking the first global estimation of the mortality benefit for individuals with HFrEF.
Dr. Gregg Fonarow, the senior author of the study, emphasized the regional disparities that exist worldwide in managing heart failure and highlighted the condition’s complexity based on socioeconomic and cultural factors. The findings underscore the urgent need to address heart failure as a global health issue and mobilize efforts to bring life-saving interventions to individuals worldwide.
The study’s projections on the potential number of lives saved each year serve as a wake-up call for the public and the medical community, demonstrating the magnitude of the problem and the critical need for prompt therapeutic interventions globally. By optimizing the implementation of guideline-directed medical therapy, we can make significant strides in reducing mortality rates and improving outcomes for individuals with heart failure.
For more information, the study titled “Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure” can be accessed in JAMA Cardiology. The research was conducted by the University of California, Los Angeles.
